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Abstract 
 
Lung cancer is the leading cause of cancer deaths worldwide with 5-year survival rate 
less than 20%. The most common subtype of lung cancer is non-small cell lung cancer 
(NSCLC) accounts for more than 80% of all lung cancers. Many epidemiological 
observations have linked estrogen signaling with worse lung cancer prognosis and poor 
survival. Previous reports have shown that estrogen can enhance the proliferation of lung 
cancer cells through activation of human epidermal growth factor receptor (EGFR/HER1) 
pathway by inducing their ligands release suggesting a functional interaction between the 
two pathways. However, it is still not clear whether other receptors and ligands within 
HER family are also involved in response to estrogen and how estrogen receptor and 
HER receptors modulate each other in lung cancer. Here, we showed that HER3 and 
HER2 were also activated upon short treatment with 17β-estradiol in a ligand-dependent 
manner. Estradiol treatment induced rapid and robust release of nuregulin-1 (NRG-1), the 
main ligand for HER3 receptor that upon binding initiates hetero-dimerization with other 
HER receptors, most likely HER2. Pharmacological inhibition of HER family with pan-
HER tyrosine kinase inhibitor, dacomitinib, and estrogen receptors with fulvestrant 
showed an enhanced inhibitory effect against HER receptors and their downstream 
signaling. Interestingly, we observed that inhibiting either pathways led to upregulation 
of the other indicating a compensatory mechanism has taken place. Active NRG-1 and 
ampiregulin (AREG) as well as their mRNA expression were elevated with fulvestrant, 
and ERβ and aromatase mRNA expression were upregulated with dacomitinib. Dual 
therapy strongly suppressed c-Myc and Cyclin D1 and both drugs worked synergistically 
to inhibit cell growth and induce apoptosis across many NSCLC cell lines that harbor 
different driving mutations. We therefore have a substantial evidence for new 
combination therapy in NSCLC that worth further investigation in vivo models of lung 
cancer. 
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INTRODUCTION:  
LUNG CANCER EPIDEMIOLOGY AND RISK: 
Recent statistics from Word Health Organization have shown that cancer is one of the 
leading cause of death worldwide. According to the World Cancer Report 2014, cancer 
caused more than 8 million deaths in the world, and among those deaths, 1.6 million were 
due to lung cancer. Lung cancers are carcinomas malignancies that arise mostly from 
epithelial cells lining the airways and are characterized by different appearance and size 
of the malignant cells. Histologically, lung carcinomas are classified into two main 
subtypes: non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). The 
most important risk factor associated with lung carcinomas is smoking, which accounts 
for more than 75% of all cases [1]. Smokers tend to have tenfold higher risk to develop 
lung cancer than lifetime non-smokers [2]. Other factors are thought to be excessive 
alcohol consumption, air pollution and aerosol exposure.  
 
Nearly 20%, of all cases are classified as SCLC, a most aggressive subtype of lung 
cancers with very poor prognosis and survival rate [3]. The majority of lung cancers 
(approximately 80%) are classified as NSCLC that is morphologically divided into three 
main types; squamous cell carcinoma (SCC), adenocarcinomas (ADC), and large-cell 
carcinoma (LCC). While there are many targeted agents approved to treat NSCLC, the 5-
year survival rate remains low with less than 20%. ADC, the most common subtype of 
NSCLC, develops centrally in the distal airways usually associated with distinct driving 
mutations while SCC arises in the proximal airways and mostly seen among smokers. A 
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minor portion of NSCLC is considered as LCC in which the tumor lacks any descriptive 
features of ADC or SCC (Fig 1) [4].  
 A                                                                     B 
 
Figure 1: (A) Lung carcinomas subtypes. (B) Histological classification of lung cancers. Top left: 
Adenocarcinoma. Top right: Squamous cell carcinoma. Bottom left: Large cell carcinoma. Bottom right: 
Small cell carcinoma. From (Lung Cancer: Peter J. Mazzone, Humberrto K. Choi, Duc Ha; Published: 
March 2014; Cleveland Clinic)   
 
As in any other solid tumors, surgery is the standard and most curative treatment 
modality to treat lung cancer. Patients undergo surgery usually have better survival rate; 
however, more than 75% of lung cancer patients are diagnosed in advanced stage where 
the tumor is no longer resectable. Chemotherapy is the centerpiece of treatment in 
majority of patients with higher response rate seen in SCLC than in NSCLC [1]. Some 
patients have certain driving mutations that are primary responsible for cancer 
development and metastasis have been recently targeted with targeted agents.  
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Over 60% of adenocarcinomas [5] and 50-80% of squamous cell carcinomas [6] have 
driving mutations that render the tumor addicted to the oncogenic effect of the mutant 
signal: a phenomenon called oncogenic addiction (Fig 2) [7]. Most of these mutations 
occur in protein kinases and cell surface receptors that have the ability to induce signaling 
cascade responsible for cell proliferation and survival such as MAPK and PI3K-AKT-
mTOR pathways. Overexpression of certain receptors makes the cell hyper responsive to 
trigger intracellular signaling even in presence of normal level of growth factors or 
ligands. Several targeted agents have been developed to target aberrant receptor tyrosine 
kinase such as epidermal growth factor receptors (EGFR) and anaplastic lymphoma 
kinase rearrangement (ALK). These targeted agents are very effective in controlling the 
disease and improve patients’ outcomes and quality of life [8, 9, 10, 11]. However, after 
initial response, patients ultimately develop resistance to those targeted therapy with a 
variety of mechanisms. Other common mutations are K-ras mutation, which accounts for 
more than 30% of adenocarcinoma and have yet to be targeted [12], and MET 
amplification with 3-7% frequency in adenocarcinoma [13]. 
Figure 2: Oncogenic 
driver mutations in 
NSCLC. From 
(Targeted therapy for 
non-small cell lung 
cancer: current 
standards and the 
promise of the future; 
Hughes BG [14]) 
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EPIDERMAL GROWTH FACTOR RECEPTOR SIGANLING PATHWAY:  
EGF family of receptors consists of four main members that are structurally similar, 
ERBB1/EGFR/HER1, ERBB2/HER2/NEU, ERBB3/HER3, and ERBB4/HER4, with 
distinct properties of each one. They are transmembrane receptors consist from three 
domains: an extracellular ligand domain, transmembrane domain, and intracellular 
tyrosine kinase domain (Fig 3). There are more than 11 identified growth factors like 
family shown to serve as agonist for HER receptors (Fig 4). These include EGF, 
amphiregulin (AREG), transforming growth factor-alpha (TGF-α), heparin-binding EGF 
like growth factor (HB-EGF), epiregulin (EPR), betacellulin (BTC), epigen (EPG), 
neuregulins/heregulins (NRGs/HRG). These ligands collectively modulate the activity of 
ErbB receptors knowing that none bind to HER2 and HER3 lacks intrinsic tyrosine 
kinase activity [15]. 
 
Figure 3 & 4: (3) The structure of HER receptor.  (4) HER dimers and their ligands. From (Targeting 
the human EGFR family in esophagogastric cancer; Ian Chau [16])  
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Ligand binding promotes the receptors homo- and/or hetero-dimerization leading to 
phosphorylation of tyrosine residues by the intracellular domain that results in activation 
of protein kinase, which then create a site for adaptor protein to bind and induce 
downstream signaling. Signaling by HER family is of principle importance in controlling 
cell proliferation, survival and differentiation (Fig 5). For example, the RAS/RAF/MEK 
pathway involves in cell proliferation and PI3K/AKT/mTOR pathway in apoptosis, cell 
cycle regulation and survival [6, 17, 18].  
 
Figure 5: The main downstream signaling pathways of HER. From (Integration of EGFR inhibitors with 
radiochemotherapy; Theodore S. Lawrence [19]) 
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Dysregulation of EGF receptors signaling causes excessive intracellular activity that 
leads to cell proliferation and metastasis. The dependency of tumor on any mutation 
within this family of growth receptors renders the cancer to be sensitive to such inhibitor 
that specifically target the aberrant receptor. Studies have shown that the frequency of 
EGFR mutation in NSCLC is 15-20% and is more prevalent among non-smokers and 
lung adenocarcinomas [20]. The mutation occurs mostly within exons 18-21 in EGFR 
gene and leads to an enhanced autocatalysis of the tyrosine kinase with more than 
threefold increase in the activity compared to wild-type EGFR (Fig 6). The most 
common mutations are point mutation of L858R in exon 21 and deletion of E746_A750 in 
exon 19 together accounting for more than 85% of all EGFR mutations in NSLCL [10, 
21, 22].  
 
 
Figure 6: The frequency of EGFR mutations in lung adenocarcinomas. From (Epidermal growth factor 
receptor mutations in lung adenocarcinoma; Alain C. Borczuk [23]) 
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The discovery of EGFR TKI was originally based on the observation that 50-80% of 
NSCLC showed EGFR overexpression. In unselected populations of lung cancer, 
gefitinib, EGFR TKI, showed some clinical benefits with response rate of 10-20% [24]. 
However, more dramatic results were seen in certain subgroups, including never-smoker 
adenocarcinoma patients [25, 26], which later turned out to be the EGFR activating 
mutations that sensitize the tumor to the TKI. EGFR tyrosine kinase inhibitors bind 
reversibly or irreversibly to the ATP binding site in the kinase domain of HER receptor. 
While most of the current targeted agents target only EGFR receptor, some have shown 
activity against multiple members within HER family of receptors. The first generation of 
EGFR targeted agents are gefitinib and erlotinib, both are reversible EGFR TKI, while 
the second generation represented with afatinib exhibits broader activity against 
EGFR/HER2 with irreversible kinase binding properties. All the three agents are 
approved for first line use in NSCLC with EGFR mutation (Exon 19 or 21 mutation).  
 
ROLE OF ESTROGEN IN LUNG CANCER: 
Several epidemiological reports have linked estrogen to lung cancer development. In 
2002, it was estimated that nearly 50% of women diagnosed with lung cancer were non-
smokers and more than 85% of men were smokers suggesting an impact of non-smoking 
related factors in lung cancer development in women [27, 28]. Women who have used 
hormonal therapy have higher risk of developing lung cancer than those who did not [29, 
30]. In addition, postmenopausal women tend to have better survival rate compared to 
their male counterparts as well as have less extensive disease at the time of diagnosis 
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compared to premenopausal women (Fig 7) [31, 32]. This suggests that high circulating 
estrogen might have a negative impact on lung cancer prognosis. 
 
 
A                                                                   B 
 
Figure 7: (A) Probability of survival in elderly lung adenocarcinoma patients based on gender. (B) 
Probability of survival in never smoking female patients divided by the menopausal status. From (Estrogen 
adversely affects the prognosis of patients with lung adenocarcinoma; Shu-Huei Kao [32]).  
 
ESTROGEN RECEPTORS IN LUNG CANCER: 
Estrogen receptors, as members of nuclear receptors family, are classified into two main 
subtypes with different isoforms of each; ERα with at least three identified isoforms and 
ERβ with five isoforms. Both receptors display different tissue distributions, with ERβ as 
the predominant subtype in lung tissue and ERα in breast, ovarian and endometrial 
tissues. ERβ was detected in majority of lung tumors comprised mainly of full-length 
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proteins, while ERα was rarely detected [33].  In various NSCLC cell lines and different 
xenografts models, only selective ERβ agonists were able to induce proliferation and 
tumor growth, while selective ERα agonist showed no activity suggesting that the effect 
of estrogen in lung cancer is mainly mediated by ERβ [34].  
Estrogen promotes proliferation in NSCLC through two main pathways (Fig 8):  
1) Genomic pathway. The genomic pathway involves mainly ERβ. Estrogen 
receptors remains in the cytoplasm bound to an inhibitory complex. When 
estrogen agonist, 17β-estradiol/E2, binds to the receptor, it promotes receptor 
dimerization and translocation to the nucleus, where it binds to estrogen response 
elements in the promoters of several target genes.  
2) Non-genomic pathway. Estrogen is known to rapidly activate non-genomic 
signaling through modulation of cell surface proteins leading to activate 
downstream signaling of MAPK and PI3K. This rapid activation promotes gene 
transcription and protein function and is considered the primarily responsible for 
full response of estrogen in lung cancer.  
Figure 8: Estrogen signaling 
in lung cancer. From 
(Chakraborty: 2010 [35]) 
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AMPHIREGULIN (AREG):  
Amphiregulin (AREG) is one of the ligands for HER receptors that operates exclusively 
through EGFR/HER1 receptor. AREG is synthesized as transmembrane precursor that 
needs to undergo proteolytic cleavage to be released and binds to the EGFR. The ligand 
has been extensively linked to the oncogenic process and its expression associated with 
worse prognosis in several cancers. It has been also reported that AREG expression 
associated with resistance to current cytotoxic therapies and multi-kinase inhibitors [36].  
 
NEUREGULIN-1/HEREGULIN-1 (NRG-1): 
The neuergulins family is one of the largest subtype of growth factors polypeptides that 
activate HER receptors. Four genes have been identified (Neuregulin1-4) with several 
isoforms. These isoforms are synthesized as pre-NRG on the cell membrane and released 
by cell surface proteases. NRG1-2 bind to both HER3 and HER4, while NRG3-4 bind o 
only HER4. NRG’s expression has been linked with several malignancies including 
breast, lung and ovarian cancer as well as endocrine and chemotherapy resistance [37].  
 
FULVESTRANT: 
 Fulvestrant (Fig 9) is a novel estrogen receptor antagonist that block the activity of both 
ERα and ERβ. It was first approved in 2002 by the Food and Drug Authority (FDA) to be 
used for hormone receptor positive breast cancer. In breast cancer, Fulvestrant works by 
binding to estrogen receptor with higher affinity than estradiol leading to receptor 
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destabilization and degradation. It has been shown to be effective as second line therapy 
for patients with breast cancer whom their tumors progressed after first line therapy.  
 
Figure 9: Fulvestrant, anti-estrogen 
 
DACOMITINIB (PF-00299804): 
Dacomitinib (Fig 10) is an investigational pan-HER tyrosine kinase inhibitor. It 
irreversibly binds to the ATP pocket in the kinase domain of HER receptors including 
EGFR, HER2, and HER4. In preclinical data, dacomitinib, compared to first generation 
TKIs, has preferable pharmacokinetic properties and wide spectrum activity against HER 
receptors [38]. Currently, it is under investigation in various clinical trials for different 
malignancies including lung, head and neck cancer and forms of glioma. 
 
Figure 10: Dacomitinib: pan-HER tyrosine kinase inhibitor.  
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The expression and functionality of estrogen receptor in lung cancer have been 
extensively investigated. Our lab previously has shown that 17β-estradiol (E2) was able 
to induce cellular proliferation and increase tumor growth in established NSCLC cell 
lines and xenografts models. Conversely, inhibiting estrogen receptor with fulvestrant or 
estradiol synthesis with aromatase inhibitor led to significant growth inhibition of lung 
tumor xenografts [33]. The mechanism by which estrogen induce proliferation is thought 
to be through a non-genomic signaling. A short treatment with E2 induces EGFR ligands 
release including TGF-alpha and HB-EGF by which then can activate the growth factor 
receptors and enhance downstream proliferative signals [39]. However, it is not clear 
whether HER2 and HER3 are involved in the mitogenic effect of estrogen in lung cancer. 
In breast cancer, activation of HER, possible in consort with HER3, is a key survival 
mechanism for breast cancer cells to overcome endocrine signaling inhibition [40, 41, 
42]. It is possibly that the effect of estrogen in lung cancer may involve HER2 and HER3 
pathway in a ligand dependent fashion. Exploring how estrogen receptor and HER family 
interact with each other to reinforce downstream proliferative signaling in NSCLC might 
provide a rational for new combination approach that will maximally inhibit cell growth.  
 
Our first goal was to study whether short treatment of NSCLC cell lines with estrogen 
receptor agonist, E2, will involve activation of HER receptors and its downstream 
signaling pathways. We used two different adenocarcinoma cell lines, a wild-type EGFR 
(201T) and a mutant EGFR (H3255). Western blot revealed a very rapid activation of 
HER3, HER2 and EGFR in 201T and EGFR and HER2 in H3255 upon 10 and 30 
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minutes treatment with E2. Analysis of the conditioned media that were collected in the 
same experiment revealed a robust release of soluble NRG-1, a primary ligand for HER3, 
and a significant increase of AREG in E2 treated groups. Interestingly, the combination 
of antiestrogen, fulvestrant, and pan-HER TKI, dacomitinib, significantly inhibited HER 
family receptors and their downstream signaling MAPK and Akt to a greater extent than 
TKI alone. However, fulvestrant by itself was able to induce NRG-1 and AREG mRNA 
expression in two cell lines; the wild-type EGFR (201T) and the mutant EGFR 
(HCC827). More interestingly, ERβ and aromatase mRNA expression were also 
upregulated with dacomitinib when used for 24hr. Blocking both pathways with 
fulvestrant and dacomitinib significantly suppresses AREG and NRG-1 mRNA 
expression as well as c-MYC and CyclinD1. We observed that more cells were 
undergoing apoptosis in the combination group as we detected that by flow cytometry 
and PARP cleavage. In terms of cell viability assays, fulvestrant and dacomitinib worked 
synergistically to inhibit cell growth in various NSCLC cell lines including K-ras mutant 
cell line: A549. Lastly, treating the cells with the pan-HER TKI, dacomitinib, 
significantly led to more cell growth inhibition than selective EGFR TKI, erlotinib, when 
both combined with fulvestrant. 
 
RESULTS: 
E2 induces rapid activation of HER receptors in two different NSCLC cell lines. 
To determine the effect of estrogen on HER receptors, we treated 201T and H3255 
NSCLC cell lines with E2 at 10nM for 10 and 30 minutes after they have been serum 
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starved for 24hr. The conditioned media and lysates were collected for ELISA and 
Western blotting analysis. For Western blot, we probed for phosphorylated molecules for 
various HER receptors and downstream signaling. We observed a significant increase in 
HER receptors activation within 10 minutes in both cell lines (Fig 11). All three HER 
receptors: EGFR, HER2, and HER3, were activated upon E2 treatment confirming the 
hypothesis that the non-genomic signaling of estrogen involves not only EGFR, but also 
HER2 and HER3 signaling. However, we were not able to detect HER3 in the H3255 cell 
line.  
 
 
 
Figure 11: (Left: 201T and Right: H3255) Activation of HER receptors following 10 and 30 
minutes treatment with 10nM E2. Ethanol was used as a negative control to E2.  
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The activation of HER receptors by E2 is ligand-dependent through inducing NRG-1 and 
AREG release. 
 Analysis of the collected conditioned media by ELISA revealed a robust increase in 
NRG-1 as well as a modest but significant increase in AREG in the treated groups of 
201T (Fig 12 A and B). We were not able to detect any of those ligands in H3255. 
Possibly, other ligands might be involved in this process in H3255 that do not include 
NRG-1 or AREG.  
 
 
 
Figure 12 A: Significant increase in NRG-1 levels following estradiol treatment at concentration of 
10nM for 30 minutes in 201T (* P value < 0.001). Abbreviations: eth = ethanol. E2 = 17β-estradiol. 
* 
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Figure 12 B: Significant increase in AREG levels detected by ELISA assay following estradiol 
treatment at 10nM concentration for 30min in 201T. (* P value < 0.05) Abbreviations: eth = ethanol. E2 = 
17β-estradiol. 
 
Dual therapy suppresses HER receptor activation as well as their downstream signaling 
 Considering our first observation that estrogen signaling activates in a non-genomic 
fashion HER pathway, we sought to determine whether blocking both pathways would 
have an enhanced effect in suppressing HER pathway and its downstream signaling. In 
order to determine that, we first performed a dose response curve for dacomitinib to 
identify the concentration that would cause 50% inhibition of cell growth using 
GraphPad Prism. (Fig 13,14). We then performed Western blot for lysates from 201T 
and HCC827, another NSCLC EGFR mutant cell line that express all four receptors of 
HER family unlike the H3255, in which they were treated for 6 hours with fulvestrant at 
5uM and dacomitinib at the identified IC50 for each cell lines. Probing for 
* 
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phosphorylated molecules of the four HER receptors, MAPK and Akt, we observed a 
stronger suppression of HER signaling with the combination compared to either agents 
alone (Fig 15,16). The suppression seen over all HER receptors including HER4 in 
HCC827 (not detected in 201T). 
 
Figure 13: IC50 for dacomitinib in 201T measured after 72 hours treatment (* IC50 = 10μM) 
 
 
Figure 14: IC50 for dacomitinib in HCC827 measured after 72 hours treatment (* IC50 36nM). 
* 
* 
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Figure 15: Inhibition of p-EGFR, p-HER2, p-HER3, p-MAPK and p-Akt following 6 hours 
treatment with fulvestrant, dacomitinib, or the combination in 201T  
 
Figure 16: Inhibition of HER kinases and their downstream signaling, MAPK and AKt, 
following 6 hours treatment with fulvestrant, dacomitinib or the combination in HCC827. 
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Blocking estrogen pathway upregulates NRG-1 and AREG mRNA expression. 
We sought to determine the effect of blocking estrogen pathway on HER pathway on the 
long exposure. We treated two cell lines, 201T and HCC827 with fulvestrant at 5μM for 
24hr. The RT q-PCR data revealed an upregulation of both NRG-1 and AREG mRNA 
expression (Fig 17, 18, 19, 20). Here the cancer cell tries to compensate for the inhibition 
of estrogen signaling by upregulating HER ligands that will eventually activate HER 
family. This important observation provides a rational for combination therapy of 
blocking both pathways in NSCLC. 
 
 
 
Figure 17: Fold change of AREG mRNA expression normalized to GAPDH following fulvestrant 
treatment in 201T using DMSO as control. (* P value < 0.006) 
* 
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Figure 18: Fold change of NRG-1 mRNA expression normalized to GAPDH following fulvestrant 
treatment in 201T using DMSO as control. ( * P value < 0.005) 
 
 
Figure 19: Fold change of AREG mRNA expression normalized to GAPDH following fulvestrant 
treatment in HCC827 using DMSO as control. ( * P value < 0.006) 
* 
* 
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Figure 20: Fold change of NRG-1 mRNA expression normalized to GAPDH following fulvestrant 
traetment in HCC827 using DMSO as control. ( * P value < 0.005) 
 
 
Blocking HER family with pan-inhibitor upregulates ERβ and Aromatase mRNA 
expression 
We asked whether blocking HER receptors would have an impact on estrogen signaling, 
so we used a pan-HER TKI that block the kinase activity of all HER receptors, 
dacomitinib, in 201T at the identified IC50. Interestingly, after 24hr treatment, the RT q-
PCR data showed an upregulation of ERβ and aromatase mRNA expression (Fig 21, 22). 
At the same time point, we measured estradiol levels by using estradiol ELISA assay. As 
expected, the estradiol was high in the media of fulvestrant group and was significantly 
less in dacomitinib treated group (Fig 23). Because the estradiol was no longer able to 
* 
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bind to its receptor under fulvestrant condition, it was accumulated in the conditioned 
media. However, the cells under dacomitinib turns on the estrogen pathway by 
consuming E2 trying to compensate the HER inhibition. This data confirmed the cross-
talk between estrogen signaling and HER pathways by showing that blocking either one 
of them will upregulate the other providing a rational for dual inhibition in NSCLC.   
 
 
 
 
Figure 21: Fold change of ERβ mRNA expression normalized to GAPDH following single or 
dual therapy in 201T using DMSO as control. (* significant difference compared to control with 
P value < 0.007) 
* 
* 
   23 
 
 
Figure 22: Fold change of aromatase mRNA expression normalized to GAPDH following single 
or dual therapy in 201T using DMSO as control. (* significant difference compared to control 
with P value < 0.006) 
 
 
Figure 23: 17β-estradiol ELISA detection following 24 hours treatment with single or dual 
therapy in 201T. (* significant difference compared to control with P value < 0.01) 
* 
* 
* 
* 
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Dual inhibition of estrogen signaling and HER kinases significantly suppressed mRNA 
expression of AREG, NRG-1, c-Myc and Cyclin D1 
We sought then to determine the expression status of HER ligands as well as genes 
responsible for cell cycle regulation and proliferation following dual inhibition. We 
treated 201T cell line at 5μM concentration of fulvestrant and at the identified IC50 of 
dacomitinib for 24hr. The RT q-PCR revealed a significant downregulation of AREG, 
NRG-1, c-Myc and Cyclin D1 mRNA expression following dual inhibition (Fig 24, 25, 
26, 27). In addition, after 24 hours of treatment, the ELISA showed a suppression of 
fulvestrant-induced release of NRG-1 and AREG when dacomitinib was added (Fig 24, 
25). 
 
Figure 24: Left: Fold change of AREG mRNA expression normalized to GAPDH following single or 
dual therapy in 201T using DMSO as control. (* compared to control. ** compared to all individual agents 
and control. * P vlaue < 0.002 for fulvestrant, < 0.01 for dacomitinib. ** P value < 0.007). Right: AREG 
ELISA showed that dacomitinib suppressed the fulvestrant-induced AREG release after 24 hours treatment. 
( * compared to control and ** compared to control and fulvestrant with P value < 0.005) 
** 
* 
* 
** ** 
* 
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Figure 25: Left: Fold change of NRG-1 mRNA expression normalized to GAPDH following single or 
dual therapy in 201T using DMSO as control. (** compared to indivsual therapy or control with P value for 
all < 0.003). Right: NRG-1 ELISA showed that both drugs induced NRG-1 release while the combination 
has no effect. (** compared to indivsual therapy with P value for all < 0.003) 
 
Figure 26: Top right: detection of c-Myc protein expression by Western blotting. The graph is showing 
the fold change of c-Myc mRNA 
expression normalized to 
GAPDH following single or 
dual therapy in 201T using 
DMSO as control. (** compared 
to indivsual therapy or control 
with P value for all < 0.004) 
** 
** 
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Figure 27: Top right: 
Detection of Cyclin D1 
protein expression by Western 
blotting. The graph is showing 
the fold change of Cyclin D1 
mRNA expression normalized 
to GAPDH following single or 
dual therapy in 201T using 
DMSO as control. (** 
compared to indivsual therapy or control with P value for all < 0.005) 
 
 
The combination synergistically inhibits the cell growth of multiple NSCLC cell lines with 
different driving mutations. 
Adding fulvestrant to dacomitinib produced a synergistic antiproliferative effect in 
several NSCLC cell lines including wild-type EGFR (201T), K-ras mutant lung 
adenocarcinoma cell line (A549), and the two EGFR mutant cell lines (HCC827, and 
H3255) (Fig 28 A, B, C, and D). The combination index values were all below 0.5 
indicating a strong synergism based on Chou Talalay’s Theorem (Fig 29) [43]. We used 
one concentration of fulvestrant, 5μM, with various concentrations of dacomitinib. The 
range of dacomitinib concentrations among the four cell lines was not the same as the 
EGFR mutant cell lines were very sensitive to dacomitinib with IC50 in the nano-range 
while the wild-type EGFR and K-ras were less sensitive with IC50 more than 10uM. 
When evaluating apoptosis in 201T, we saw a marked increase in PARP cleavage with 
** 
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the combination at 72hr as an indication of apoptosis induction (Fig 30). We also 
measured how many cells were undergoing apoptosis under dual and single treatments by 
flow cytometry using Annexin V-FITC apoptosis detection assay. Within only 5 hours 
of treatment, adding fulvestrant to dacomitinib led to more cells undergoing apoptosis 
compared to dacomitinib or fulvestrant alone (Fig 31). 
 
 
A 
 
 
Dacomitinib nM 1 2.5 5 10 
Fulvestrant uM 5 5 5 5 
Combination Index CI 0.005 0.02 0.08 0.02 
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B 
 
 
Dacomitinib uM 5 10 15 20 25 
Fulvestrant uM 5 5 5 5 5 
Combination Index CI 0.30 0.41 0.57 0.58 0.4 
 
C 
 
Dacomitinib nM 1 10 50 
Fulvestrant uM 5 5 5 
Combination Index CI 0.09 0.17 0.4 
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D 
 
Dacomitinib uM 1 5 10 15 20 25 
Fulvestrant uM 5 5 5 5 5 5 
Combination Index CI 0.14 0.16 0.06 0.04 0.02 0.009 
 
Figure 28 A, B, C and D: MTS assay following combination therapy in H3255, 201T, HCC827 and 
A549 cell lines.  
 
 
Figure 29: The ranges of CI 
values defined and described by 
Ting-Chao Chou. CI < 1, = 1, > 1, 
indicate synergism, additive effect, 
and antagonism, respectively. From 
(Ting-Chao Chou: 2006 [43]) 
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Figure 30: Western blot analysis for PARP with 201T following 72 hours treatment with single or dual 
therapy using anti-actin antibody as loading control. 
 
 
 
 
Figure 31:  Percentage of Apoptotic cells were detected in 201T after 5 hours treatment by flow 
cytometry. (* compared to control or either agents alone with P value < 0.004) 
* 
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Targeting HER signaling with pan-HER TKI yielded in more cell growth inhibition 
compared to selective EGFR when both combined with antiestrogen in NSCLC cell lines  
Considering our observation that blocking estrogen signaling might on the long exposure 
upregulate HER ligands including HER3 and HER4 ligand, we sought to compare adding 
fulvestrant to dacomitinib or erlotinib, a selective EGFR TKI. While fulvestrant 
significantly enhanced the cytotoxic effect of both TKIs, a much greater effect was seen 
with dacomitinib than erlotinib in 201T and H3255 cell lines (Fig 32).  
 
 
 
** 
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Figure 32: MTS assay in 201T and H3255 cell lines following fulvestrant, erlotinib, and dacomitinib 
treatment in single or dual therapy for 72 hours. (** compared to Fulvestrant + Erlotinib with P value < 
0.008) 
 
 
 
DISCCUSION:  
Giving the compelling evidence of the role of estrogen in lung cancer and the 
accumulated epidemiological observations of more non-smoker females are diagnosed 
with lung cancer, we aimed here at studying the mechanism by which estrogen can 
enhance proliferation in NSCLC cells in vitro. Our lab previously has shown that short 
treatment of NSCLC cells for 10 minutes with E2 induces rapid response of activating 
p44/42 MAPK though EGFR ligands release. In breast cancer, the role of HER2/HER3 
** 
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signal is well investigated as one of the primary mechanisms of resistance to endocrine 
therapy. We have shown here that within 30 minutes EGFR, HER2, and HER3 were 
activated in a ligand dependent manner. NRG-1, as the main ligand for HER3, was 
potently induced with estradiol suggesting that HER3, possibly in consort with HER2, is 
regulated by estrogen. Since HER3 lacks intrinsic tyrosine kinase activity, it possibly 
undergoes dimerization when it is activated with HER2, which has tyrosine kinase 
activity and lacks ligand binding activity. This observation has led us to combine 
fulvestrant, as antiestrogen, with pan-HER TKI, dacomitinib, in various NSCLC cell 
lines. After 6 hours of the treatment, we were able to inhibit all the HER receptors with 
the combination to a much greater extent than either drugs alone. This promising effect 
was seen also against downstream signaling of HER including MAPK and Akt. In breast 
cancer, it was reported that fulvestrant after 48 hours differentially regulates EGFR 
ligands. In fact, AREG was shown to be downregulated and there was no effect seen on 
NRG-1 expression [44]. However, we observed here that fulvestrant in 201T and 
HCC827 cell lines induced mRNA expression of AREG and NRG-1. This implies a 
compensatory mechanism by the cells to overcome the estrogen signaling inhibition that 
could limit the antiproliferative effect of fulvestrant in lung cancer. We also showed that 
dacomitinib induced ERβ and aromatase mRNA expression after 24 hour suggesting that 
activation of estrogen pathway might be an escaping mechanism for the cell to survive 
under HER receptor inhibition. This upregulation of estrogen pathway with dacomitinib 
was accompanied with less estradiol detected in the conditioned media indicating a 
possible activation of estrogen signaling. Together, these observations brought us to a 
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conclusion that there is a cross-talk between estrogen receptor and ErbB family in lung 
cancer and blocking either pathways will eventually upregulate the other as a survival 
mechanism. Therefore, targeting both pathways could have an enhanced antiproliferative 
effect. Indeed, the cell proliferation assays showed a synergistic effect of adding 
fulvestrant to dacomitinib across multiple NSCLC cell lines. The dual inhibition 
significantly suppressed mRNA expression of the common proliferative gene, c-Myc, as 
well as the cell cycle regulation gene, Cyclin D1. In addition, the combination induced 
significantly more apoptosis as we observed that in term of PARP cleavage, which was 
markedly increased, and detection of apoptotic cells by flow cytometer. Lastly, targeting 
all HER receptors with pan-HER TKI led to more cell growth inhibition compared to 
only targeting EGFR when both combined with fulvestrant. A possible explanation is that 
fulvestrant might activate HER2/HER3 signal through inducing NRG-1 expression, 
which cannot be effectively suppressed by erlotinib.   
 
 
 
FUTURE DIRECTION: 
The non-genomic signaling of estrogen in lung cancer involves not only EGFR to 
enhance the proliferation, but also HER2 and HER3 in the same pattern. Considering that 
HER3 lacks intrinsic tyrosine kinase activity that it most likely forms a dimer with other 
HER receptors, it is possible that estrogen can enhance the homo or/and 
heterdimerization of those receptors. A question that can be answered by performing co-
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immunopercipitaion of HER2 or HER3 with other members of the family following 
estradiol treatment. In order also to verify the regulation of HER pathway by fulvestrant, 
we will use small interference RNA against ERβ. This will tell us exactly how ERβ 
regulates HER receptors and their ligands expression. We will also investigate how 
blocking HER activity can activate estrogen signaling by looking for estrogen-specific 
target genes. Finally, with the promising results of the combination in vitro and in several 
cell lines, we will move forward and test the combination in vivo models including 
orthotopic model of NSCLC growth in immunocompromised mice and in patients-
derived NSCLC xenografts (PDXs). We will assess the antiproliferative effect and 
identify some biomarkers that will predict the response to the combination. 
 
 
COUNCLUSION: 
In conclusion, we have established here that the non-genomic signaling of estrogen 
involves several members of HER family of receptors that includes not only EGFR, as it 
has been shown before, but also HER2 and HER3. We have shown that each pathway 
regulates the other when one of them is pharmacologically inhibited providing a rational 
for combination therapy. The dual therapy synergistically inhibited the cell growth in 
different NSCLC cell lines (Fig 32). 
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Figure 32: The non-genomic signaling pathway of estrogen involves activation of EGFR, 
HER2 and HER3 through promoting their ligands release, NRG-1 and AREG. Following 
long exposure to antiestrogen therapy or HER kinase inhibition, NSCLC cells elicit 
compensatory mechanisms in which they upregulate AREG and NRG-1 mRNA 
expression under fulvestrant condition and ERβ and aromatase mRNA expression with 
dacomitinib.   
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MATERIALS AND METHDOS: 
Reagents and cell culture 
NSCLC cell lines 201T (was established in our laboratory from primary tissue) and A549 
(obtained from American Type Culture Collection, Manassas, VA, USA) were 
maintained in 37ºC and 5% CO2. 201T was grown in basal medium eagle (BME) with 
10% fetal bovine serum, 2mM of L-Glutamine and 50X Penicillin Streptomycin all 
purchased from GIBCO by Life technologies. The other NSCLC cell lines H3255 and 
HCC827 were obtained from American Type Culture Collection and were grown in 
Roswell Park Memorial Institute Medium (RPMI) with 10% fetal bovine serum, 2mM of 
L-Glutamine and 50X Penicillin Streptomycin. Rabbit monoclonal EGFR (4267 ;1:1000), 
HER2 (4290 ;1:1000), HER3 (12708 ;1:1000), HER4 (4795 ;1:1000), β-actin (8457 
;1:1000), p44/p42 MAPK (4695 ;1:1000), Akt (4691 ;1:1000), and cleaved-PARP (5625 
;1:1000) antibodies were obtained from Cell Signaling Technology (Beverly, MA, USA). 
The pan-HER tyrosine kinase inhibitor (dacomitinib; S2727) and antiestrogen 
(fulvestrant; S1191) were purchased from Selleckchem (TX, USA). Rabbit monoclonal 
phospho-EGFR Tyr1068 (#3777;1:1000), phosphor-HER2 Tyr 1221/1222 
(#2234;1:1000), phosphor-HER3 Tyr1289 (#4791, 1:1000), phosphor-HER4 Tyr1284 
(#4757; 1:1000), phosphor-p44/p42 MAPK (#8544; 1:1000), phosphor-Akt (#4060; 
1:1000), c-Myc (#5605), Cyclin D1 (#2978), and anti-rabbit IgG HRP-liked (#7074; 
1:2000) antibodies were all purchased from Cell Signaling Technology (Beverly, MA, 
USA). Human Neuregulin1 ELISA kit (DY377) and Amphiregulin ELISA kit (DY262) 
were purchased from R & D systems (Minneapolis, MN, USA). 17β-estradiol/E2 
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(E8875) was purchased from Sigma-Aldrich (St. Louis, MO, USA). Cell Titer Aqueous 
One Solution Cell Proliferation Assay was obtained from Promega (Madison, WI, USA). 
Supersignal West Pico Chemiluminescent Substrate (1:1) was purchased from Thermo 
Scientific (Waltham, MA, USA). Immobilon -P transfer membrane for Western blot was 
purchased from Millipore corporation (Billerica, MA, USA). Triazol® reagent 
(15596026) for RNA isolation was obtained from Thermo Scientific (Waltham, MA, 
USA).qScript™ cDNA synthesis Kit and SYPR green kit were obtained from Quanta 
Biosciences (Beverly, MA, USA). The following primer sequences for quantitative PCR 
were synthesized at BioMedical Genomic Center at University of Minnesota:  
NRG-1: 
 Forward: 5’-GCCAGGAATCGGCTGCAGGT-3’ 
 Reverse: 5’-AGCCAGTGATGCTTTGTTAATGCGA-3’ 
AREG: 
 Forward: 5’-GTGGTGCTGTCGCTCTTGATA -3’ 
 Reverse: 5’-ACTCACAGGGGAAATCTCACT -3’ 
c-Myc: 
 Forward: 5’-AATGAAAAGGCCCCCAAGGTAGTTATCC-3’ 
 Reverse: 5’-GTCGTTTCCGCAACAAGTCCTCTTC-3’ 
Cyclin D1: 
 Forward: 5’-GCTGCTAAGTGGAAACCATC -3’ 
 Reverse: 5’-CCTCCTTCTGCACACATTTGA -3’ 
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ERβ: 
 Forward: 5’-CCCTGCTGTGATGAATTACAG -3’ 
 Reverse: 5’-CGGTTCCCACTAACCTTCC -3’ 
Aromatase:  
 Forward: 5’-CACATCCTCAATACCAGGTCC-3’ 
 Reverse: 5’-CAGAGATCCAGACTCGCATG -3’ 
GAPDH: 
 Forward: 5’-AGCCACATCGCTCAGACAC-3’ 
 Reverse: 5’-GCCCAATACGACCAAATCC-3’ 
 
 
Cell treatment and Immunoblotting  
For estradiol treatment experiment, 450,000 cells from 201T and H3255 were plated in 6-
well plate with 10% FBS. Once they became confluent, they were serum starved in a 
serum free and phenol red free media for 24 hours. They were then treated with E2 at 
10nM or ethanol for 10 and 30 min. The cells were washed with cold phosphate-buffered 
saline (PBS) and lysed with RIPA lysis buffer. Lysates were then centrifuged to remove 
insoluble part at 12,000g centrifugation for 30 minutes at 4ºC. Protein concentrations 
were measured using Bradford assay kit from BIO-RAD Company. Samples were 
prepared from each treatment groups in both cell lines at 50μg protein concentration in 
4X NuPAGE LDS sample buffer with BME and RIPA buffer. Samples were heated at 
100ºC for 10 minutes to denaturate proteins.  60μl of each samples were loaded in each 
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well of the gel. Gels were prepared using handcasting polyacrylamide gels from BIO-
RAD Company at 7.5% concentration with 10% APS and TMED. Gels were run for one 
and a half hours at 100 volts then proteins were transferred to PVDF membrane 
(Immobilon-P) for one and a half hours at 100 volts. Membranes were blocked with 5% 
milk prepared in T-BST for one hour followed by overnight incubation at 4ºC with p-
EGFR, p-HER2, P-HER3, p-HER4, p-MAPK, p-AKt, and Actin. The membranes then 
were washed three times, each for 15 minutes, with TBST then were blocked with 
secondary antibody (anti-rabbit IgG HPR liked) for one hour. Membranes were washed 
three times again with TBST and developing solution was added (Supersignal West Pico 
Chemiluminescent 1:1) for 5 minutes. Developing films were obtained from the X-ray 
films company.  
 
To determine the effect of the combination therapy on ErbB phosphorylation and 
downstream signaling, 450,000 cell from 201T and HCC827 cell lines were plated in 6-
well plates. After they reached the desired confluence, they were treated with DMSO 
(negative control), fulvestrant at 5μM, and dacomitinib at 10μM for 201T and 10nM for 
HCC827, or the combination of fulvestrant and dacomitinib for 6 hours. Lysates were 
collected following the abovementioned procedure and immunoblotting was performed 
using p-EGFR, p-HER2, p-HER3, p-HER4, p-MAPK, p-Akt, c-Myc, Cyclin D1 and 
Actin monoclonal antibody. The blots were stripped using Restore Western Blot 
Stripping Buffer from Thermo Scientific (21059) and reprobed with loading controls 
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including anti-EGFR, anti-HER2, anti-HER3, anti-HER4, anti-p44/p42 MAPK and anti-
Akt monoclonal antibodies.  
 
In order to determine the effect of dual therapy on PARP cleavage as a sign of apoptosis, 
350,000 cells of 201T were plated in 6 well plates. After 24 hours, they were treated with 
DMSO, fulvestrant, dacomitinib, or the combination for 72 hour. Cells were then washed 
with cold PBS and lysed using the abovementioned techniques. 40μg of protein was used 
from each lysates and immunoblotting was conducted as mentioned above using cleaved-
PAPR monoclonal antibody. The blot was stripped and reprobed with loading control 
anti-actin antibody.  
 
ELISA assay 
In order to determine the effect of estradiol treatment in ligands release, we plated 
450,000 cells from 201T and H3225 cell lines in 6-well plates. They have been serum 
starved with phenol red free media for 24 hour after they reached the desired confluence. 
Estradiol was added in a new starvation media at 10nM for 30 minutes using ethanol as a 
negative control. The conditioned media were then collected and centrifuged at 12,000 g 
centrifugation for 10 minutes at 4ºC. The insoluble fractions were discarded and the 
supernatant used in ELISA assay for AREG and NRG-1 detection following the company 
protocols.  
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To determine the levels of AREG and NRG-1 in the conditioned media following single 
or dual therapy, we plated 450,000 cells from 201T in 6-well plates. They have been 
serum starved for 24 after they have reached the desired confluence. The media were 
replaced with new media containing DMSO, fulvestrant, dacomitinib, or the combination. 
The conditioned media then were collected and centrifuged at 12,000 g for 10 minutes at 
4ºC to remove any insoluble fractions. Following the manufacture’s protocol, AREG and 
NRG-1 were measured in triplicates.  
 
 
Reverse Transcription –quantitative real-time polymerase chain reaction (qRT-
PCR)  
To determine the effect of long exposure to either fulvestrant, dacomitinib or the 
combination in 201T, 450,000 cells were plated in 6 well plate for 24 hour. Once they 
reached confluence, they have been treated with either DMSO, Fulvestrant at 5μM, 
dacomitinib 10μM, or the combination of fulvestrant and dacomitinib for 24 hour. The 
cells then washed with cold PBS and lysed using Trizol® reagent. Following the 
company protocol for RNA isolation, a total 2μg of RNA was reversed transcribed using 
QuntaBio cDNA synthesis kit according to the company instructions. Quantitative PCR 
was performed using PerfeCTa SYPR® Green Supermix using primers for NRG-1, 
AREG, c-MYC, Cyclin D1, ERβ, aromatase and GAPDH.  
 
  
   43 
 
Cell viability assay 
To measure the cytotoxic effect of the combination of fulvestrant and dacomitinib in all 
four cell lines, 10,000 cells from each cell lines were plated in 96-well plates at 100ul 
volume. The cells then were incubated for 72 hours in a 1% FBS phenol red free media 
containing DMSO or the combination. Fulvestrant, at a constant concentration of 5μM 
was combined with various concentrations of dacomitinib in all four cell lines. The 
absorbance was measured at 490nM using microplate reader instrument after adding 10ul 
MTS assay reagent in each well and incubated for 1 hour. The IC50 for dacomitinib was 
identified for 201T and HCC827 using GraphPad Prism and the combination index 
values were calculated using CompuSyn software based on Chou Talalay’s Theorem.  
 
FITC Annexin V apoptosis assay 
To assess the effect of the combination on apoptosis, 300,000 cells from 201T were 
plated in 6 well plates. Following the manufacture’s protocol for FITC Annexin V 
Apoptosis Detection Kit (BD Pharmingen), the cells were stained with FITC Annexin V 
and/or Propidium Iodide (PI) and analyzed within one hour using BD LSR II/Fortessa 
machine located at Cancer and Cardiovascular Research Building in University of 
Minnesota.   
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